

RECEIVED
REGION 1

Superior Medical Diagnostics II, LLC

231 Franklin Ave.

Nutley, New Jersey 07110

(201) 941-7575 Fax. (201) 941-1660

2002 APR 10 AM 10: 22

030-35993

LL 3 0730

02201

USNRC REGION 1
LICENSING MATERIAL SECTION
475 ALLENDALE ROAD
KING OF PRUSSIA, PA 19406-1415

RE: NRC PET LICENSE APPLICATION

APRIL 8, 2002

To Whom It May Concern:


Enclosed is a complete application for a NRC radioactive materials license for our facility. We have used Regulatory Guide 10.8 Revision 2 in the preparation of this application. Note that this is a dedicated PET department and therefore, require licensing for dose calibrator testing for linearity (Tc-99m) and constancy (Cs-137).

Note that we will only use doses available from the local radiopharmacy. We will not use generators, aerosols or radioactive gas. We do not request the use of I-131 in amounts to exceed 30 uCi and therefore, do not require a Quality Management Program (QMP). Additionally, since we are not a medical institution, a Radiation Safety Committee is not needed.

Please contact us with the correct fee and we will immediately send a check. It is our intention to begin scanning patients for diagnosis in early June 2002.

Should you have any questions regarding this application, please feel free to contact me. Please note, because we are in the process of renovations of the facility at 231 Franklin Avenue, Nutley N.J., please forward all correspondence to our home office at 178 Bergen Boulevard P.O. Box 99 Fairview, N.J. 07022.

Sincerely,


John Galdi, Sr.

JG/lg

1 3 1 3 2 3

NMSS/RGNI MATERIALS-002
NMSB1

Superior Medical Diagnostics II, LLC
231 Franklin Avenue
Nutley, New Jersey

NRC LICENSE APPLICATION

NRC Form 313

Item 5 and 6 Radioactive Material and Purpose for which licensed material will be used

Byproduct Material	Amount	Purpose
5a. Material in 35.100	As needed	6a. Medical use
5b. Material in 35.200	As needed	6b. Medical Use
Cs-137 Reference Vial	< 250 uCi	Dose calibrator QC

Item 7 Individual Responsible for Radiation Safety Program and their training and experience

The Radiation Safety Officer for this facility will be **Charles Anthony Giomuso, MS**. Mr. Giomuso will be given sufficient authority to act as the Radiation Safety Officer of our facility. He is our Medical Physicist as well. For training and experience, refer to the enclosed document.

We wish to have **Paul H. Pevsner, M.D.** listed as our Authorized User. For training and experience for Dr. Pevsner, refer to the enclosed documents.

Item 8 Training for individuals working in or frequenting the restricted area

We will establish and implement the model training program that was published in **Appendix A of Regulatory Guide 10.8 Revision 2**. We will train only those individuals that work with or in the vicinity of the restricted area of the Nuclear Medicine Department. This group of individuals would be the treadmill technologist, nuclear medicine technologist and nursing support. This training will occur once the employee has been hired and annually thereafter. Documentation of training will be available in the Nuclear Medicine Department for review.

Item 9.1 Facility and Equipment

Refer to the enclosed room diagram.

Equipment:

Hitachi Sceptre PET scanner

Atom Lab 300 Dose Calibrator or equivalent

1 Ludlum model 14C survey instruments with pancake probe or equivalent

Model 44-2 scintillation probe to be interfaced to Ludlum 14C survey meter for wipe testing

Item 10.3 Leak Testing of sealed sources

Leak tests of sealed sources will be done in accordance with model program for leak testing sources that was published in **Appendix H of Regulatory Guide 10.8 Revision 2** so that our Medical Physicist can perform analysis of leak tests on location.

Item 10.4 Radiation Safety Rules

We will establish and implement the Model Safety Rules for the laboratory that are published in **Regulatory Guide 10.8 Appendix I**.

Item 10.5 Spill Procedures

We will establish and implement the Model Spill Procedures published of **Regulatory Guide 10.8 Appendix J**.

Item 10.6 Ordering and Receiving

We will establish and implement the Model Procedure for ordering and receiving radioactive material published in **Regulatory Guide 10.8 Appendix K**.

Item 10.7 Opening Packages

We will establish and implement the Model Procedure for opening radioactive material published in **Regulatory Guide 10.8 Appendix L**. In addition, we will comply with 10 CFR Part 20 in opening packages containing radioactive material.

Item 10.8 Unit Dose Records

We will establish and implement the Model Procedure for Unit Dosage Record System published in **Regulatory Guide 10.8 Appendix M1**.

Item 10.9 and 10.10 Multi-dose Vial Records

We will establish and implement the Model Procedure for Multi-dose Vial Records published in **Regulatory Guide 10.8 Appendix M2**. We will only use doses that have been prepared by the local radiopharmacy and therefore, they will keep molybdenum concentration records.

Item 10.11 Inventory of Implant sources

Not Applicable

Item 10.12 Area Surveys

We will establish and implement the Model Procedure for Area Surveys that is published in **Regulatory Guide 10.8 Appendix N**. The table listed in this guide will be used for action levels for both restricted and unrestricted areas. The action level for surveys will be 2.0 mR/hr for restricted areas and 0.05 mR/hr for unrestricted areas. In addition, we will not expose members of the general public to greater than 100 mrem/year in an unrestricted area.

Item 10.13.1 and 10.13.2 and 10.13.3 and 10.13.4

We do not plan on using aerosol or radioactive gases at this time.

Item 11.1 Waste Management

We will establish and implement the General Guidance and Model Procedures for Waste Disposal that is published in **Regulatory Guide 10.8 Appendix R**.

Survey Meter Calibration

Survey meters will be sent to an NRC or Agreement State vendor that has been approved for calibration of survey instruments.

Dose Calibrator Calibration

We will establish and implement the Model Procedure for calibration of a dose calibrator that is published in **Regulatory Guide 10.8 Appendix C**. If the accuracy, constancy and activity linearity evaluations exceed +/- 10%, we will repair or replace the unit.

Personnel Monitoring

We will establish and implement the Model Procedure for Personnel External Monitoring Program that is published in **Regulatory Guide 10.8 Appendix D**.

Radiation Safety Committee

Since we are not a medical institution, a Radiation Safety Committee is not required.

ALARA

We will establish and implement the Model ALARA Procedure that is published in **Regulatory Guide 10.8 Appendix G**. In addition, the duties of the Radiation Safety Officer will be implemented that are listed in this Appendix.

Use of I-131

We will not use I-131 in amounts greater than 30 uCi and therefore do not require a Quality Management Program.

Decommissioning

In the event that we wish to terminate our license, we will notify the Nuclear Regulatory Commission as well as the State of New Jersey. We will then perform a close out survey at all places where radioactive materials were used or stored. The survey will consist of area monitoring with a calibrated low-level meter. In addition, wipe tests will be performed in the same areas to check for removable contamination. The trigger levels will be set at any reading above background for the area surveys and no greater than 2000 DPM per 100 square centimeters for wipe tests. All sealed sources would either be returned to the vendor or transferred to an authorized user of radioactive materials that will be verified prior to that transfer. In addition, we will comply with the requirements as set forth in Chapter 2 of the Draft Report of NUREG/CR-5849.

**23J Franklin Avenue
Nutley, New Jersey**

Assumptions:

- * F-18 has a Specific gamma ray constant (Γ) of 6.0 R/hr/mCi
- * 10 mCi is typical dose for patient
- * Consider the patient the source on the table and holding area
- * The closest member of the general public would be 8 feet away
30.48 cm/ft x 8 feet = 243.8 cm
- * The half value layer of lead for 511 keV is 4.01 mm
- * Regulations state you cannot exceed 100 mrem/yr to the general public or 2.0 mr/hr in any one hour

Calculations based on 10 mCi injected


$$\text{Exposure rate} = \Gamma (\text{mCi}) / d^2$$

$$\frac{6 \text{ R/hr/mCi} \times 10 \text{ mCi}}{30.48 \text{ cm/ft} \times 8 \text{ feet} = 243.8 \text{ cm}^2} = 0.9 - 1.0 \text{ mr/hr @ approx. } 8'$$

Therefore, if the wall were in place with 4.1 mm of shielding, this would reduce the exposure by one half of the 1.0 mr/hr. The exposure at that distance would then be approximately 0.5 mr/hr. The value of 4.1 mm of lead is slightly less than 2 sheets of 1/8" (6.2 mm) of lead placed together and tacked on the wall. So the exposure with 2 sheets in place (slightly greater than the calculated 2 HVL's) should be less than the calculated 0.5 mr/hr.

2 sheets of 1/8" lead will be placed on the designated walls going up 7 feet making it a 1/4" leaded wall.

**234 Franklin Avenue
Nutley, New Jersey**





American

OPEN MRI CENTER, P.C.

MRI, CAT SCANS, NUCLEAR MEDICINE, ULTRASOUND,
DIAGNOSTIC RADIOLOGY, MAMMOGRAPHY AND ECHOCARDIOGRAPHY
111-20 QUEENS BLVD., FOREST HILLS, NY 11375
TEL: (718) 263-3915 . FAX: (718) 263-4415

SHIRISH K. THANAWALA, M.D., DIRECTOR OF RADIOLOGY
DIPLOMATE, AMERICAN BOARD OF RADIOLOGY
DIPLOMATE, AMERICAN BOARD OF NUCLEAR MEDICINE

GERALD J. SCHULZE, M.D., ASSOCIATE RADIOLOGIST
DIPLOMATE, AMERICAN BOARD OF RADIOLOGY

February 13, 2002

To whom it may concern:

This is to certify that Dr. Paul H. Pevsner has been reading Nuclear Medicine Scans under my supervision for the past two years at the above named facility which generated an average of 162 scans in 2000 and 103 scans in 2001.

If I can be of further assistance, please do not hesitate to contact me.

Sincerely,

Shirish K. Thanawala, M.D.
Radiologist

SKT/gb

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS			KEY TO COLUMN C	
FULL NAME Paul H. Pevsner, M.D.			PERSONAL PARTICIPATION SHOULD CONSIST OF:	
STREET ADDRESS [REDACTED]			1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.	
CITY [REDACTED] STATE [REDACTED] ZIP CODE [REDACTED]			2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.	
			3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.	

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C		COMMENTS D <i>(Additional information or comments may be submitted in duplicate on separate sheets.)</i>
		1972	1973	
I-131 or I-125 * *	DIAGNOSIS OF THYROID FUNCTION *			The case numbers in Column C and on the attached page represent total examinations performed in the Department of Nuclear Medicine at Johns Hopkins Hospital in 1972 and 1973. I was involved personally with approximately 10% of these examinations during my four months rotation and periodic call rotation on the Nuclear Medicine service during this period.
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	14	52	
	LIVER FUNCTION STUDIES	12	20	
	FAT ABSORPTION STUDIES			
	KIDNEY FUNCTION STUDIES	134	394	
IN VITRO STUDIES				
OTHER *	See accompanying page			
I-125	DETECTION OF THROMBOSIS	64	10	
I-131	THYROID IMAGING	400	300	
P-32	EYE TUMOR LOCALIZATION	---	---	
Se-75	PANCREAS IMAGING	44	38	
Yb-169	CISTERNOGRAPHY	128	210	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	160	640	
OTHER	*			
Tc-99m	BRAIN IMAGING	2228	4244	
	CARDIAC IMAGING	50	86	
	THYROID IMAGING	188	838	
	SALIVARY GLAND IMAGING	2	-	
	BLOOD POOL IMAGING	114	92	
	PLACENTA LOCALIZATION	12	4	
	LIVER AND SPLEEN IMAGING	998	2182	
	LUNG IMAGING	1032	1716	
BONE IMAGING	190	736		
OTHER				


PERSONAL INFORMATION WAS REMOVED BY NRC. NO COPY OF THIS INFORMATION WAS RETAINED BY THE NRC.

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION		COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
		1972 C	1973	
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES			
P-32 (Colloidal)	INTRACAVITARY TREATMENT			
I-131	TREATMENT OF THYROID CARCINOMA			
	TREATMENT OF HYPERTHYROIDISM			
Au-198	INTRACAVITARY TREATMENT			
Co-60 or Cs-137	INTERSTITIAL TREATMENT			
	INTRACAVITARY TREATMENT			
I-125 or Ir-192	INTERSTITIAL TREATMENT			
Co-60 or Cs-137	TELE THERAPY TREATMENT			
Sr-90	TREATMENT OF EYE DISEASE			
	RADIOPHARMACEUTICAL PREPARATION			
Mo-99/ Tc-99m	GENERATOR	60	70	
Sn-113/ In-113m	GENERATOR	10	--	
Tc-99m	REAGENT KITS	40	60	
Other				

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING
 1972 - 1973 4 months continuous rotation and monthly on-call rotation

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF: a. NAME OF SUPERVISOR Henry Wagner, M.D. b. NAME OF INSTITUTION Johns Hopkins Hospital c. MAILING ADDRESS 615 N. Wolfe Street d. CITY Baltimore, Maryland 21205	6. PRECEPTOR'S SIGNATURE 
	7. PRECEPTOR'S NAME (Please type or print) Henry N. Wagner, Jr., M.D.
	8. DATE 5/7/81.
	5. MATERIALS LICENSE NUMBER(S) MD07005-03

Isotope	Conditions Diagnosed or Treated	Number of Cases Involving Personal Participation	
		1972	1973
T _c -99M	Cerebral Angiogram	698	1944
"	RES (Reticulo-endothelial Bone Marrow)	178	302
"	Mini-Leg (venous thrombosis)	64	70
"	Lymph Node Scan	16	-
"	Abdomen Scan	12	-
"	Liver - Lung	--	8
I-125 or I-131	Thyroid Uptake	746	1454
"	PBI	2	6
"	Resin T ₃	1536	2432
"	Thyroxin (T ₄)	1536	2432
"	Digoxin	--	118
"	Perchlorate discharge	--	8
IN - 113M	Peripheral Circulation Study	30	10
	Liver - Spleen	66	--
Ga - 68	Abscess - Tumor	258	275
Cr - 51	RBC - Volume	40	76
	RBC - Survival	80	14
	Splenic Sequestration	6	14
	G-I Blood Loss	36	12
Co-57	Vitamin B-12 Absorption	180	206
Fe-59	Ferrokinetics	--	12
F-18	Bone Scan	10	--
Sr-85	Bone Scan	14	--

**TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER**

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER Paul H. Pevsner, M.D.	2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE
---	--

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
American Board of Radiology	Diagnostic Radiology	December 1973

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	1970 - 1974 Johns Hopkins Hospital, Departments of Nuclear Medicine and Radiology	50 hrs	
b. RADIATION PROTECTION	"	30 hrs	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	"	20 hrs	
d. RADIATION BIOLOGY	"	20 hrs	
e. RADIOPHARMACEUTICAL CHEMISTRY	"	20 hrs	

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
see page 6 and attachments				

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION		COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
		1972	1973	
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES			
P-32 (Colloidal)	INTRACAVITARY TREATMENT			
I-131	TREATMENT OF THYROID CARCINOMA			
	TREATMENT OF HYPERTHYROIDISM			
Au-198	INTRACAVITARY TREATMENT			
Co-60 or Cs-137	INTERSTITIAL TREATMENT			
	INTRACAVITARY TREATMENT			
I-125 or Ir-192	INTERSTITIAL TREATMENT			
	TELETHERAPY TREATMENT			
Co-60 or Cs-137	TELETHERAPY TREATMENT			
	TREATMENT OF EYE DISEASE			
Sr-90	TREATMENT OF EYE DISEASE			
	RADIOPHARMACEUTICAL PREPARATION			
Mo-99/ Tc-99m	GENERATOR	60	70	
Sr-113/ In-113m	GENERATOR	10	---	
Tc-99m	REAGENT KITS	40	60	
Other				

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING
 1972 - 1973 4 months continuous rotation and monthly on-call rotation

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:


a. NAME OF SUPERVISOR
Henry Wagner, M.D.

b. NAME OF INSTITUTION
Johns Hopkins Hospital

c. MAILING ADDRESS
615 N. Wolfe Street

d. CITY
Baltimore, Maryland 21205

5. MATERIALS LICENSE NUMBER(S)
MD07005-03

6. PRECEPTOR'S SIGNATURE


7. PRECEPTOR'S NAME (Please type or print)
Henry N. Wagner, Jr., M.D.

8. DATE
5/7/81.

Isotope	Conditions Diagnosed or Treated	Number of Cases Involving Personal Participation	
		1972	1973
T _c -99M	Cerebral Angiogram	698	1944
"	RES (Reticulo-endothelial Bone Marrow)	178	302
"	Mini-Leg (venous thrombosis)	64	70
"	Lymph Node Scan	16	-
"	Abdomen Scan	12	-
"	Liver - Lung	--	8
I-125 or I-131	Thyroid Uptake	746	1454
"	PBI	2	6
"	Resin T ₃	1536	2432
"	Thyroxin (T ₄)	1536	2432
"	Digoxin	--	118
"	Perchlorate discharge	--	8
IN - 113M	Peripheral Circulation Study	30	10
	Liver - Spleen	66	--
Ga - 68	Abscess - Tumor	258	275
Cr - 51	RBC - Volume	40	76
	RBC - Survival	80	14
	Splenic Sequestration	6	14
	G-I Blood Loss	36	12
Co-57	Vitamin B-12 Absorption	180	206
Fe-59	Ferrokinetics	--	12
F-18	Bone Scan	10	--
Sr-85	Bone Scan	14	--

**TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER**

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

Paul H. Pevsner, M.D.

2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
American Board of Radiology	Diagnostic Radiology	December 1973

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	1970 - 1974 Johns Hopkins Hospital, Departments of Nuclear Medicine and Radiology	50 hrs	
b. RADIATION PROTECTION	"	30 hrs	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	"	20 hrs	
d. RADIATION BIOLOGY	"	20 hrs	
e. RADIOPHARMACEUTICAL CHEMISTRY	"	20 hrs	

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
see page 6 and attachments				

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Marrik Health Systems, Inc.	3. License No. 45-25516-01
2. 759 Welton Avenue Roanoke, Virginia 24015	4. Expiration Date: July 31, 2010
	5. Docket No. 030-35377

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 35.100	A. Any form for uses described in § 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Cs-137	C. Reference vial	C. < 9.25 Megabequerels (250 microcuries)

9. Authorized Use:

- A. Medical use identified in 10 CFR 35.100
- B. Medical use identified in 10 CFR 35.200
- C. Dose calibrator quality control

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 315 Hospital Drive, Martinsville, Virginia, 24112.
- 11. The Radiation Safety Officer for this license is Charles Anthony Giomuso, MS.


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.
45-25406-01

Docket No.
030-34544

- 12. Licensed material listed in Item 6 above shall be used by, or under the supervision of Craig Turner, DO.
- 13. Sealed sources containing licensed material shall not be opened by the licensee.
- 14. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.
- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated May 8, 2000.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION
ORYSIA MASNYK BAILEY

DATE JUL 12 2000

BY *Orysia Masnyk Bailey*
Region II, Division of Nuclear Materials Safety
61 Forsyth Street, S.W., Suite 23T85
Atlanta, Georgia 30303

This is to acknowledge the receipt of your letter/application dated

04-08-02, and to inform you that the initial processing which includes an administrative review has been performed.

- NEW* *030-35993*
- There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information. *Please contact FEES AT Hqs. - 310-415-6055 for cost of license.*
- Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number **131323**.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

Sincerely,
Licensing Assistance Team Leader

BETWEEN: : (FOR LFMS USE)
 : INFORMATION FROM LTS
 : -----
 :
 License Fee Management Branch, ARM : Program Code: 02201
 and : Status Code: 3
 Regional Licensing Sections : Fee Category: _____
 : Exp. Date: 0
 : Fee Comments: _____
 : Decom Fin Assur Reqd: _
 : ::

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: SUPERIOR MEDICAL DIAGNOSTICS II, LLC
 Received Date: 20020410
 Docket No: 3035993
 Control No.: 131323
 License No.:
 Action Type: New Licensee

2. FEE ATTACHED

Amount: _____
 Check No.: /

3. COMMENTS

Signed Rebecca J. Brown
 Date 04-13-02

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /__/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:

Amendment _____
 Renewal _____
 License _____

3. OTHER _____

Signed _____
 Date _____